"Scripps Research in La Jolla announced a new clinical trial Thursday that will assess the effectiveness of using drugs approved for diabetes treatment and weight loss to treat long COVID, the debilitating chronic condition diagnosed in an estimated 20 million Americans and about 400 million people worldwide. Developed to help people with type 2 diabetes control their blood sugar levels, these GLP-1 medications have generated"
"And growing evidence of its anti-inflammation properties, notes Scripps computational biologist and study co-principal investigator Julia Vogel, has driven increasing interest in using GLP-1 drugs to treat at least some of long COVID's myriad symptoms, which range from brain fog and difficulty breathing to fatigue and joint pain. The trial, which seeks to enroll 1,000 long COVID patients nationwide, will explore how self-administration of tirzepatide,"
"GLP-1 drugs have been found to do so many different things, Vogel said. They've helped with all kinds of immune conditions, in part by reducing inflammation, and we know that is an issue in long COVID. Desperate for therapies that work, the long COVID community has already begun experimenting with microdosing GLP-1 drugs, with a post made one year ago on the social news site Reddit entitled Ozempic for Long Covid? reporting anecdotal evidence of the drug helping some improve their symptoms."
Scripps Research in La Jolla launched a randomized clinical trial to evaluate GLP-1 drugs for long COVID symptoms by enrolling 1,000 patients nationwide for a 12-month treatment period. The trial will test self-administration of tirzepatide, an Eli Lilly GLP-1 agonist approved for diabetes and weight loss. GLP-1 medications slow digestion, reduce appetite, and have anti-inflammatory effects that may address immune-related long COVID symptoms such as brain fog, breathing difficulty, fatigue, and joint pain. Researchers cite growing preclinical and clinical interest in repurposing GLP-1 compounds for cardiovascular, kidney, and sleep disorders. Patient communities report anecdotal microdosing experiences.
Read at www.sandiegouniontribune.com
Unable to calculate read time
Collection
[
|
...
]